Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q4 and the full year ended December 31, 2020, on March 9, 2021, at 8:30 am Eastern Time. The conference call will feature leadership including CEO Erez Raphael and CFO Zvi Ben-David. Participants are encouraged to join 10 minutes early. A replay will be available two hours post-call until April 9, 2021. DarioHealth focuses on digital therapeutics, providing evidence-based interventions for those with chronic conditions, including diabetes, through its MyDario™ app.

DarioHealth Corp. (Nasdaq: DRIO) has announced its participation in the Cowen 41st Annual Health Care Conference, set to take place virtually from March 1-4, 2021. CEO Erez Raphael and President Rick Anderson will present on March 1st at 11:00 a.m. ET. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions aimed at managing chronic conditions like diabetes and hypertension. The company emphasizes personalized experiences and clinically proven tools to foster health improvements.

DarioHealth Corp. (Nasdaq: DRIO) is set to participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24 to 26, 2021. CEO Erez Raphael will host investor meetings during the event, emphasizing Dario's role in the digital therapeutics market. The company is known for its AI-powered solutions aimed at chronic condition management, particularly in diabetes and hypertension. DarioHealth is expanding its reach across various health conditions and geographic markets, focusing on personalized experiences and evidence-based interventions.

DarioHealth Corp. (Nasdaq: DRIO) has announced its acquisition of Upright Technologies Ltd., a digital musculoskeletal (MSK) company, in a stock transaction valued at $31 million. This move expands Dario's digital therapeutic platform, which already serves around 150,000 users, by adding a clinically validated MSK solution that aligns with its focus on chronic conditions. Concurrently, Dario secured $70 million through a private placement to enhance its cash reserves, aiming to fortify its market position. The transaction is expected to close on or about February 7, 2021.

DarioHealth Corp. (Nasdaq: DRIO) announced the addition of Dr. Marilyn Ritholz and Dr. David Horwitz to its Scientific Advisory Board, enhancing its digital therapeutics platform aimed at chronic condition management. The SAB's mission includes leveraging their expertise to improve clinical offerings and market penetration. Dr. Ritholz specializes in diabetes and behavioral health, while Dr. Horwitz has extensive experience in clinical affairs at major diabetes organizations. This strategic move is expected to further advance Dario's AI-driven health solutions, focused on personalized care.

DarioHealth Corp. (NASDAQ: DRIO) has appointed Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships, a new role aimed at enhancing their sales strategy. Ms. Kraut brings extensive experience from her previous role at Omada Health, where she built strong partnerships. Rick Anderson, President of North America, expressed confidence that her expertise will accelerate growth opportunities in 2021 and beyond. The company emphasizes its innovative digital therapeutic solutions aimed at chronic condition management, further strengthening its market position.

DarioHealth Corp. (Nasdaq: DRIO) announced a pivotal agreement to provide its digital therapeutics solution to eligible employees of a subsidiary of a Fortune 500 technology company. This marks Dario's first self-insured employer client via the partnership with Vitality Group. The program, focusing on diabetes and hypertension solutions, will start enrolling members in January 2021. DarioHealth emphasizes its personalized, adaptive healthcare approach, aiming to improve employee health outcomes and reduce care costs.

DarioHealth Corp. (Nasdaq: DRIO) announced a partnership with Presbyterian Medical Services to deliver its remote patient monitoring (RPM) solution starting January 1, 2021. This collaboration aims to enhance care for patients with chronic conditions like diabetes and hypertension. Following a rigorous evaluation process, Dario's AI-powered RPM was selected for its superior technology and ability to improve patient engagement and health outcomes. The financial details of the agreement were not disclosed.